Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Eagon, P. K.
Right arrow Articles by Rao, K. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eagon, P. K.
Right arrow Articles by Rao, K. N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 20, No. 6, 1091-1096, June 1999
© 1999 Oxford University Press


Carcinogenesis

Hepatic hyperplasia and cancer in rats: alterations in copper metabolism

Patricia K. Eagon1,2,3,5, Annette G. Teepe3, Mary S. Elm1,2, Stasa D. Tadic1,2, Marilyn J. Epley1,2, Bonnie E. Beiler4, Hisashi Shinozuka4 and Kalipatnapu N. Rao4

1 VA Medical Center, Pittsburgh, PA 15240,
2 Department of Medicine,
3 Department of Molecular Genetics and Biochemistry and
4 Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA

We previously demonstrated that rats exposed to the peroxisome proliferator (PP) diethylhexylphthalate (DEHP) had reduced serum ceruloplasmin (CP) oxidase activity, which suggests tissue copper deposition. Copper is highly toxic in excess, and results in cellular damage and hepatocellular carcinomas (HCC). This study addresses changes in expression of copper-related genes and metal accumulation in hyperplastic liver and tumors induced by PP. Male rats were fed diets containing DEHP or clofibrate (CLF) for 3–60 days (hyperplasia) and 4-chloro-6-(2,3 xylidino)-2-pyrimidinyl-thio(N-ß-hydroxyethyl) acetamide for 10 months (HCC). During hyperplasia, an immediate and progressive decrease in serum CP activity was observed (P < 0.05), as were reductions in mRNA levels for both CP and Wilson's disease gene (WD gene, a P-type ATPase) (P < 0.05). Tumor-bearing rats had lower serum CP activity (P < 0.05), and CP and WD gene mRNA levels were reduced in tumors (P < 0.05), and in liver surrounding tumors (SL) (P < 0.05). Metallothionein mRNA showed no consistent changes during hyperplasia. Tumors showed a 2.5-fold induction of metallothionein mRNA (P < 0.05), and a 1.2-fold increase in SL. Temporal increases in liver copper content occurred during hyperplasia, with increases of 2-fold (DEHP) and 3.3-fold (CLF) at 60 days (P < 0.05). Copper content was 2.2-fold higher in tumors (P < 0.05) and 1.7-fold higher in SL; iron did not increase and zinc decreased temporally. Thus, copper accumulation and changes in copper-related gene expression may be contributing factors in liver neoplasia in PP-treated rats. Loss of CP results in decreased free radical scavenger capacity and thus may enhance oxidative damage induced by PPs.

Abbreviations: BR931, 4-chloro-6-(2,3 xylidino)-2-pyrimidinyl-thio(N-ß-hydroxyethyl) acetamide; CLF, clofibrate; CP, ceruloplasmin; DEHP, di(2-ethylhexyl)phthalate; HCC, hepatocellular carcinoma; LEC, Long–Evans Cinnamon rats; MT, metallothionein; PP, peroxisome proliferator; WD gene, Wilson's disease gene or Atp7b in rat.

5 To whom correspondence should be addressed at Department of Medicine, 566 Scaife Hall, University of Pittsburgh, Pittsburgh, PA 15261, USA Email: pkeagon2+{at}pitt.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
A. Kiss, R. Ortiz-Aguayo, R. Sharp, G. Merlino, S. S. Thorgeirsson, F. J. Gonzalez, and J. M. Peters
Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation
Carcinogenesis, June 1, 2001; 22(6): 975 - 979.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
V. S. Narayanan, C. A. Fitch, and C. W. Levenson
Tumor Suppressor Protein p53 mRNA and Subcellular Localization Are Altered by Changes in Cellular Copper in Human Hep G2 Cells
J. Nutr., May 1, 2001; 131(5): 1427 - 1432.
[Abstract] [Full Text]


Home page
Toxicol SciHome page
M. L. O'Brien, T. P. Twaroski, M. L. Cunningham, H. P. Glauert, and B. T. Spear
Effects of Peroxisome Proliferators on Antioxidant Enzymes and Antioxidant Vitamins in Rats and Hamsters
Toxicol. Sci., April 1, 2001; 60(2): 271 - 278.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.